Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial
Trials volume 21, Article number: 1014 (2020)
SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synthesis contributing to alveolar collapse, worsening hypoxia and leading to respiratory failure. The objective of this study is to evaluate the feasibility, safety and efficacy of nebulised surfactant in COVID-19 adult patients requiring mechanical ventilation for respiratory failure.
This study is a dose-escalating randomized open-label clinical trial of 20 COVID-19 patients.
This study is conducted in two centres: University Hospital Southampton and University College London Hospitals. Eligible participants are aged ≥18, hospitalised with COVID-19 (confirmed by PCR), who require endotracheal intubation and are enrolled within 24 hours of mechanical ventilation. For patients unable to consent, assent is obtained from a personal legal representative (PerLR) or professional legal representative (ProfLR) prior to enrolment. The following are exclusion criteria: imminent expected death within 24 hours; specific contraindications to surfactant administration (e.g. known allergy, pneumothorax, pulmonary hemorrhage); known or suspected pregnancy; stage 4 chronic kidney disease or requiring dialysis (i.e., eGFR < 30); liver failure (Child-Pugh Class C); anticipated transfer to another hospital, which is not a study site, within 72 hours; current or recent (within 1 month) participation in another study that, in the opinion of the investigator, would prevent enrollment for safety reasons; and declined consent or assent.
Intervention and comparator
Intervention: The study is based on an investigational drug/device combination product. The surfactant product is Bovactant (Alveofact®), a natural animal derived (bovine) lung surfactant formulated as a lyophilized powder in 108 mg vials and reconstituted to 45 mg/mL in buffer supplied in a prefilled syringe. It is isolated by lung lavage and, by weight, is a mixture of: phospholipid (75% phosphatidylcholine, 13% phosphatidylglycerol, 3% phosphatidylethanolamine, 1% phosphatidylinositol and 1% sphingomyelin), 5% cholesterol, 1% lipid-soluble surfactant-associated proteins (SP-B and SP-C), very low levels of free fatty acid, lyso-phosphatidylcholine, water and 0.3% calcium. The Drug Delivery Device is the AeroFact-COVID™ nebulizer, an investigational device based on the Aerogen® Solo vibrating mesh nebulizer.
The timing and escalation dosing plans for the surfactant are as follows.
Cohort 1: Three patients will receive 10 vials (1080 mg) each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls with no placebo intervention.
Cohort 2: Three patients will receive 10 vials (1080 mg) of surfactant at dosing times of 0 hours and 8 hours, and 30 vials (3240 mg) at a dosing time of 24 hours. 2 controls with no placebo intervention.
Cohort 3: Three patients will receive 10 vials (1080 mg) of surfactant at a dosing time of 0 hours, and 30 vials (3240 mg) at dosing times of 8 hours and 24 hours. 2 controls with no placebo intervention.
Cohort 4: Three patients will receive 30 (3240 mg) vials each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls. 2 controls with no placebo intervention.
The trial steering committee, advised by the data monitoring committee, will review trial progression and dose escalation/maintenance/reduction after each cohort is completed (48-hour primary outcome timepoint reached) based on available feasibility, adverse event, safety and efficacy data. The trial will not be discontinued on the basis of lack of efficacy. The trial may be stopped early on the basis of safety or feasibility concerns.
Comparator: No placebo intervention.
All participants will receive usual standard of care in accordance with the local policies for mechanically ventilated patients and all other treatments will be left to the discretion of the attending physician.
The co-primary outcome is the improvement in oxygenation (PaO2/FiO2 ratio) and pulmonary ventilation (Ventilation Index (VI), where VI = [RR x (PIP − PEEP) × PaCO2]/1000) at 48 hours after study initiation. The secondary outcomes include frequency and severity of adverse events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs), change in pulmonary compliance, change in positive end-expiratory pressure (PEEP) requirement of ventilatory support at 24 and 48 hours after study initiation, clinical improvement defined by time to one improvement point on the ordinal scale described in the WHO master protocol (2020) recorded while hospitalised, days of mechanical ventilation, mechanical ventilator free days (VFD) at day 21, length of intensive care unit stay, number of days hospitalised and mortality at day 28. Exploratory end points will include quantification of SARS-CoV-2 viral load from tracheal aspirates using PCR, surfactant dynamics (synthesis and turnover) and function (surface tension reduction) from deep tracheal aspirate samples (DTAS), surfactant phospholipid concentrations in plasma and DTAS, inflammatory markers (cellular and cytokine) in plasma and DTAS, and blood oxidative stress markers.
After informed assent, patients fulfilling inclusion criteria will be randomised to 3:2 for the treatment and control arms using an internet-based block randomization service (ALEA tool for clinical trials, FormsVision BV) in combination with electronic data collection. Randomisation will be done by the recruiting centre with a unique subject identifier specific to that centre.
This is an open-labelled unblinded study.
Numbers to be randomised (sample size)
The total sample size is 20 COVID-19 mechanically ventilated patients (12 intervention; 8 control).
Current protocol version is V2 dated 5th of June 2020. The recruitment is currently ongoing and started on the 14th of October 2020. The anticipated study completion date is November 2021.
The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
Availability of data and materials
The study investigators will have access to the final trial dataset which will be available from the author upon request.
We would like to thank Bill and Melinda Gates Foundation for funding this study. We would like to acknowledge University Hospital Southampton Research and Development department, study managers Danny Pratt, Josune Olza Meneses, UCLH Study coordinator Subarna Roy, Roman Jastrub, Debbie Smyth and all the Critical Care Research Nursing Team at UCLH and UHS, Dr Filipa Martins (PHARMExcel), NIHR Southampton Clinical Research Facility (CRF), laboratory technicians (Madhuriben Panchal, Grielof Koster and Magdalena Minnion) Trial Steering Committee (Professor Steve Brett, Dr Luigi Camporota, Professor Kevin Dhaliwal and Dr Murali Shyamsundar) and DSM board members (Professor Monty Mythen, Professor Charlotte Summers and Professor Guy Ludbrook), eCRF developers (Nicole Vaughan-Spikers, Richard Munday), Jim Fink (Aerogen Pharma), Colin Telfer (Aerogen Pharma), Romina Weinhold (Lyomark Pharma GmbH) and Robert Diblasi for the preliminary data. We also thank the NIHR Respiratory Translational Research Collaboration and NIHR Comprehensive Clinical Research Network (CCRN) for endorsing the study.
The trial is funded by The Bill & Melinda Gates Foundation (INV-016631). The contribution of the funding body to the study is detailed below.
• Design - The funder (Bill and Melinda Gates Foundation) contributed to refining the design of the study.
• Data collection – NA.
• Data analysis - Our trial statistician (Dr Robin Mogg) is clinical biostatistics leader at the Bill and Melinda Gates Medical Research Institute which is a subsidiary of the funder (Bill and Belinda gates Foundation).
• Data interpretation - The funder will contribute to interpretation of the data. The funder has no control or right of veto over any publications.
Ethics approval and consent to participate
The study has appropriate HRA approval (HRA and Health Care Research Wales Approval number 20/NE/0149, date of approval 05/05/2020) and IRAS project ID number: 282498. All participants adults aged >18 years old will be intubated and mechanically ventilated and as a result assent will be obtained from legal or professional consultee prior to enrolment. Retrospective consent will be obtained upon recovery from patients. The schematic diagram for consenting process is detailed in the protocol.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Dushianthan, A., Clark, H., Madsen, J. et al. Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial. Trials 21, 1014 (2020). https://doi.org/10.1186/s13063-020-04944-5